VOR — Vor Biopharma Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1817229 ·
Last close
$21.15
Market Cap
$1.15B
52W High
$22.22
52W Low
$12.58
ADV30
1,548,417
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -35,160,000 | -219,585,000 | 506,746,000 | 169,873,000 | 657,170,000 |
| Dec 2025 | 0 | — | -35,960,000 | 1,722,858,000 | 464,126,000 | 396,486,000 | 628,438,000 |
| Sep 2025 | 0 | — | -28,107,000 | -812,684,000 | 176,237,000 | 160,462,000 | 2,401,724,000 |
| Jun 2025 | 0 | — | -274,284,000 | -1,573,669,000 | 205,371,000 | 190,574,000 | 1,711,071,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-149,893,000
Investing CF
$-311,809,000
Financing CF
$579,283,000
CapEx
$-758,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-383.15
As of
2026-06-07
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,372,560,000
Inventory
—
Receivables
—
ST Investments
$321,652,000
EBIT TTM
$-373,511,000
Pretax Income TTM
$-883,080,000
Interest Exp TTM
—
Analysts
8
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -371,642,000 | -695,981,000 | 464,126,000 | 628,438,000 | — | -142,713,000 |
| Dec 2024 | 0 | -121,185,000 | -116,914,000 | 142,891,000 | 46,227,000 | — | -99,660,000 |
| Dec 2023 | 0 | -126,036,000 | -117,863,000 | 198,126,000 | 47,402,000 | — | -100,292,000 |
| Dec 2022 | 0 | -93,418,000 | -92,094,000 | 299,366,000 | 48,759,000 | — | -85,144,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-3.74
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| IMTX | Immatics N.V. | $1.18B | $8.66 | — |
| MGTX | MeiraGTx Holdings plc | $1.09B | $11.79 | — |
| NVAX | NOVAVAX INC | $1.20B | $7.32 | — |
| INBX | Inhibrx Biosciences, Inc. | $1.20B | $82.05 | — |
| CGEM | Cullinan Therapeutics, Inc. | $1.01B | $16.50 | — |
News headlines (Yahoo Finance, 1h cache)
Vor Bio Appoints David Zaccardelli to Board of Directors
2026-07-07 20:01 · Yahoo
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2026-07-02 21:30 · Yahoo
Why Vor Biopharma (VOR) Is Up 24.5% After Broad FTSE Russell Index Inclusion And What's Next
2026-06-30 15:08 · Yahoo
Telitacicept Receives NMPA Approval for the Treatment of Sjögren’s Disease in China
2026-06-08 12:31 · Yahoo
Telitacicept Receives NMPA Conditional Approval for the Treatment of IgA Nephropathy in China
2026-06-08 12:30 · Yahoo
Why This Fund Made a $66 Million Bet on Damora Therapeutics Amid a 700% Surge
2026-05-30 18:12 · Yahoo
Dyne Stock Is Up 56%. Here's What a $14 Million Stake Reduction Could Mean
2026-05-30 16:48 · Yahoo
Vor Bio to Participate in the 2026 Jefferies Global Healthcare Conference
2026-05-28 12:30 · Yahoo
We're Hopeful That Vor Biopharma (NASDAQ:VOR) Will Use Its Cash Wisely
2026-05-15 12:25 · Yahoo
Vor Bio Announces Publication of Interim Analysis of TELIGAN, a China Phase 3 Trial of Telitacicept in IgA Nephropathy, in The New England Journal of Medicine
2026-05-14 12:30 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.